Rachel McMinn is the founder of Neurogene. Neurogene has raised $69M in total funding. Latest round: Series A.
Rachel McMinn, Ph.D., is the Founder and Chief Executive Officer of Neurogene. She founded the company in January 2018 with the goal of developing genetic medicines for neurologically-impaired individuals. Prior to founding Neurogene, she gained experience as Chief Business and Strategy Officer at Intercept Pharmaceuticals and as a biotechnology analyst.
Full founder directory · Investor directory · Company funding database · Fundraising library